SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1803-MM, Maintenance, Len vs Len/Dara | 1 | N | 0 Screening | 1420 | 1448 | 250 | 118 | 41 | 0 | 0 | 08/13/2019 | 330 | 128 |
1448 | 250 | 118 | 41 | 0 | 0 | |||||||||
2 | Y | 1 Lenalidomide | 669 | 120 | 56 | 21 | 1 | 1 | 08/13/2019 | |||||
2 Lenalidomide + Daratumumab | 658 | 116 | 53 | 18 | 3 | 0 | ||||||||
1327 | 236 | 109 | 39 | 4 | 1 | |||||||||
3 | Y | 3 Stop vs Continue Treatment | 252 | 81 | 49 | 30 | 16 | 1 | 08/13/2019 | |||||
252 | 81 | 49 | 30 | 16 | 1 | |||||||||
S2005-WM, Prev. Untreated, I/R +/- Venetoclax | 1 | Y | 1 I+R | 92 | 6 | 6 | 4 | 1 | 0 | 0 | 01/05/2022 | 79 | 23 | |
2 I+R+Venetoclax | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
3 V+R | 5 | 5 | 2 | 1 | 0 | 0 | ||||||||
12 | 11 | 6 | 2 | 0 | 0 | |||||||||
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | 1 | Y | 1 VRD-R | 510 | 23 | 18 | 10 | 4 | 1 | 0 | 10/12/2023 | 219 | 84 | |
2 DRD-R | 24 | 18 | 9 | 4 | 2 | 0 | ||||||||
3 DRD-DR | 22 | 17 | 9 | 4 | 2 | 0 | ||||||||
69 | 53 | 28 | 12 | 5 | 0 | |||||||||
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | 1 | Y | 0 Induction | 338 | 11 | 11 | 8 | 6 | 2 | 0 | 07/01/2024 | 133 | 42 | |
11 | 11 | 8 | 6 | 2 | 0 | |||||||||
2 | Y | 1 Dara-VCD | 2 | 2 | 2 | 1 | 1 | 0 | 07/01/2024 | |||||
2 Melphalan + ASCT | 2 | 2 | 2 | 1 | 0 | 0 | ||||||||
4 | 4 | 4 | 2 | 1 | 0 | |||||||||
3 | Y | 3 Dara | 1 | 1 | 1 | 1 | 1 | 0 | 07/01/2024 | |||||
1 | 1 | 1 | 1 | 1 | 0 | |||||||||
Yes | EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | 0 | E | Total Registrations | 52 | 6 | 3 | 2 | 1 | 1 | 05/27/2021 | 204 | 81 | |
52 | 6 | 3 | 2 | 1 | 1 | |||||||||
1 | E | Total Registrations | 37 | 3 | 1 | 0 | 0 | 0 | 05/27/2021 | |||||
37 | 3 | 1 | 0 | 0 | 0 | |||||||||
2 | E | Total Registrations | 29 | 14 | 5 | 2 | 0 | 0 | 05/27/2021 | |||||
29 | 14 | 5 | 2 | 0 | 0 | |||||||||
No | EAA173-MYEL, SMM, Rd +/- Daratumumab | 0 | E | Total Registrations | 75 | 15 | 4 | 0 | 0 | 0 | 01/08/2020 | 235 | 101 | |
75 | 15 | 4 | 0 | 0 | 0 | |||||||||
1 | E | Total Registrations | 37 | 11 | 4 | 0 | 0 | 0 | 01/08/2020 | |||||
37 | 11 | 4 | 0 | 0 | 0 | |||||||||
Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|
S2005 WM, Prev. Untreated, I/R +/- Venetoclax | 2 Crossover | 24-Jun-21 | 79 | 23 |